Ocugen (NASDAQ:OCGN) Posts Quarterly Earnings Results, Meets Expectations

Ocugen (NASDAQ:OCGN) released its quarterly earnings results on Wednesday. The company reported ($0.06) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.06), FiscalAI reports. The firm had revenue of ($0.19) million for the quarter, compared to analyst estimates of $0.86 million. Ocugen had a negative return on equity of 904.65% and a negative net margin of 1,192.18%.

Here are the key takeaways from Ocugen’s conference call:

• Enrollment is complete for the OCU400 Phase 3 liMeliGhT trial (140 patients); top-line 12‑month data are expected in Q1 2027 and a rolling BLA submission is planned to begin in Q3 2026 with commercialization targeted in 2027.
• Interim Phase 2 data for OCU410 in geographic atrophy showed a 46% reduction in lesion growth at 12 months (P=0.015) and a 50% responder rate, with full Phase 2 data due this month and Phase 3 initiation planned for 2026.
• The Stargardt program (OCU410ST) remains ahead of schedule, benefited from a peer‑reviewed Phase 1 publication and CHMP confirmation that the single U.S. trial can support an EMA application, with pivotal topline data expected in 2Q 2027.
• Cash on hand extends runway only into Q4 2026 after a recent $22.5M raise, with an extension to Q2 2027 contingent on full exercise of $30M of warrants, indicating near‑term financing risk before commercialization.
• Management and business development were strengthened in 2025 (new commercial, finance, and operations hires), plus a regional licensing deal for OCU400 in Korea and the creation of the Ocucelix subsidiary to pursue non‑core assets, supporting commercialization and value‑creation plans.

Ocugen Stock Down 11.2%

Ocugen stock opened at $1.74 on Friday. The stock’s 50 day moving average price is $1.57 and its 200 day moving average price is $1.42. Ocugen has a 1-year low of $0.52 and a 1-year high of $2.00. The company has a market cap of $543.44 million, a PE ratio of -7.57 and a beta of 2.75. The company has a debt-to-equity ratio of 8.04, a current ratio of 1.85 and a quick ratio of 1.85.

Analysts Set New Price Targets

Several brokerages have weighed in on OCGN. Chardan Capital reiterated a “buy” rating and issued a $7.00 target price on shares of Ocugen in a research note on Thursday. Weiss Ratings reiterated a “sell (e+)” rating on shares of Ocugen in a research report on Thursday, January 22nd. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average target price of $7.00.

Institutional Investors Weigh In On Ocugen

Institutional investors have recently made changes to their positions in the stock. SmartHarvest Portfolios LLC acquired a new position in shares of Ocugen during the 4th quarter worth $31,000. NewEdge Advisors LLC grew its position in Ocugen by 198.0% during the second quarter. NewEdge Advisors LLC now owns 36,814 shares of the company’s stock worth $36,000 after buying an additional 24,460 shares during the period. BNP Paribas Financial Markets increased its holdings in Ocugen by 56.7% in the second quarter. BNP Paribas Financial Markets now owns 36,822 shares of the company’s stock valued at $36,000 after buying an additional 13,326 shares in the last quarter. Schonfeld Strategic Advisors LLC acquired a new stake in shares of Ocugen during the 4th quarter valued at approximately $38,000. Finally, Caitong International Asset Management Co. Ltd raised its position in Ocugen by 28,222.4% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 30,305 shares of the company’s stock worth $41,000 after acquiring an additional 30,198 shares during the last quarter. 10.27% of the stock is currently owned by hedge funds and other institutional investors.

About Ocugen

Ocugen Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing gene therapies to treat rare inherited retinal diseases, as well as vaccines designed to address unmet needs in infectious diseases. Headquartered in Malvern, Pennsylvania, the company applies its proprietary gene therapy platform to create novel treatments aimed at preserving and restoring vision, while leveraging strategic partnerships to broaden its vaccine pipeline.

In its gene therapy portfolio, Ocugen is advancing multiple programs targeting retinal disorders.